选择性植入耐久型左心室辅助装置作为难治性心源性休克的主要治疗
该单中心回顾性研究纳入43例难治性心源性休克患者(急性心肌梗死21例、急性失代偿性心力衰竭22例),以耐久型左心室辅助装置(LVAD)作为初始治疗。手术死亡率14%(6/43),6个月和12个月Kaplan-Meier生存率分别为82.7±6.0%和73.9±8.0%,1年移植累积发生率为30.8±7.9%。作者认为该策略可取得良好的中期结局并可能有潜在获益。
要点
- 43例难治性心源性休克患者以耐久型LVAD作为初始治疗,手术死亡率14%(6/43)。
- 6个月和12个月生存率分别为82.7±6.0%和73.9±8.0%。
- 1年心脏移植累积发生率为30.8±7.9%。
核心结论
- 作者认为其数据挑战了难治性心源性休克患者最好先以临时装置稳定病情的观念。
- 作者认为以耐久型LVAD作为心源性休克的初始治疗可取得良好的中期结局并可能有潜在获益。
研究设计与样本
- 单中心回顾性研究,纳入43例连续难治性心源性休克患者,病因为急性心肌梗死(n=21)或急性失代偿性心力衰竭(n=22)。
- 所有患者均以耐久型LVAD作为初始治疗,其中轴向血流37例、离心泵4例、搏动性2例。
主要发现
- 5例(12%)同期放置右心室辅助装置(RVAD),1例延迟植入RVAD。
- 平均手术时间362分钟,平均体外循环时间94分钟,20例同期行心脏手术。
- 早期主要不良事件包括手术死亡率14%(6/43)、因出血再手术7%(3/43)、卒中4.7%(2/43)。
- 机械通气中位时间3.5天,ICU停留9天,住院25天。
- Kaplan-Meier生存率6个月为82.7±6.0%、12个月为73.9±8.0%;竞争分析示移植累积发生率6个月为10.3±5.0%、1年为30.8±7.9%。
临床怎么用
- 作者认为以耐久型LVAD作为难治性心源性休克的初始治疗可取得良好的中期结局并可能有潜在获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Surgical therapy for refractory primary cardiogenic shock is largely based on emergent placement of extracorporeal membrane oxygenation or short-term ventricular assist devices. We have adopted a strategy of routine implantation of durable left ventricular assist devices (LVAD) as initial therapy for refractory cardiogenic shock, in patients who are potential candidates for heart transplantation, and report our experience. METHODS: Retrospective review of 43 consecutive patients with refractory shock caused by acute myocardial infarction (n = 21) or acute decompensated heart failure (n = 22) who were treated with primary implantation of a durable LVAD in a single institution. RESULTS: All patients received durable LVAD (axial flow, n = 37; centrifugal, n = 4; pulsatile, n = 2), with concurrent placement of right ventricular assist device (RVAD) in 5 patients (12%). One patient had delayed RVAD implantation. Mean operative time was 362 minutes and mean cardiopulmonary bypass time was 94 minutes. Twenty patients underwent concurrent cardiac procedures. Major early adverse events included operative mortality 14% (6/43), reoperation for bleeding 7% (3/43), and stroke 4.7% (2/43). Median time on mechanical ventilation was 3.5 days, ICU stay 9 days, and hospital stay 25 days. Kaplan-Meier survival was 82.7 ± 6.0% at 6 months and 73.9 ± 8.0% at 12 months. Using competing analysis, the cumulative incidence of transplantation was 10.3 ± 5.0% at 6 months and 30.8 ± 7.9% at 1 year. CONCLUSIONS: Our data challenge the notion that patients in refractory cardiogenic shock are best served by an initial period of stabilization with temporary devices. Primary implantation of durable LVADs in cardiogenic shock can yield good midterm outcomes and may have potential benefits.
引用
- Pawale A, Schwartz Y, Itagaki S, et al. Selective implantation of durable left ventricular assist devices as primary therapy for refractory cardiogenic shock. J Thorac Cardiovasc Surg. 2017. PMID: 29274911. doi:10.1016/j.jtcvs.2017.10.136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。